Scarica l'app Stockscreener
34.56
0.95%
-0.33
Dopo l'orario di chiusura:
34.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$34.89
Aprire:
$35.14
Volume 24 ore:
600.55K
Relative Volume:
1.17
Capitalizzazione di mercato:
$1.97B
Reddito:
$681.88M
Utile/perdita netta:
$122.63M
Rapporto P/E:
16.38
EPS:
2.11
Flusso di cassa netto:
$220.18M
1 W Prestazione:
-11.34%
1M Prestazione:
-14.58%
6M Prestazione:
-6.09%
1 anno Prestazione:
+4.73%
Intervallo 1D:
$33.97
$35.30
Intervallo di 1 settimana:
$33.97
$39.50
Portata 52W:
$28.14
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
34.56 | 1.97B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Harmony Biosciences to Announce Q4 & Full Year 2024 Results on February 25, 2025 - MSN
Harmony Biosciences (NASDAQ:HRMY) Receives Buy Rating from HC Wainwright - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down After Analyst Downgrade - MarketBeat
‘Short-Tem Setback’ for Harmony Biosciences in Idiopathic Hypersomnia Application for Pitolisant - Sleep Review
Harmony Biosciences price target cut to $42 at Mizuho - Investing.com
Harmony Biosciences Faces Regulatory Setback, Outlines Future Plans for Pitolisant - MyChesCo
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $42 at Mizuho - StreetInsider.com
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder - AOL
Harmony Gets Dissonant FDA Response For Wakix In Idiopathic Hypersomnia - News & Insights
Needham & Company LLC Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $50.00 - MarketBeat
Harmony Biosciences's sleep disorder treatment gets FDA Refuse to File letter - Seeking Alpha
FDA issues RTF to Harmony Biosciences for IH drug By Investing.com - Investing.com South Africa
FDA issues RTF to Harmony Biosciences for IH drug - Investing.com India
Harmony Biosciences Receives US FDA's Refusal to File Letter Related to Application for Pitolisant in Idiopathic Hypersomnia - Marketscreener.com
Harmony Biosciences Receives FDA Refusal To File Letter For Pitolisant In Idiopathic Hypersomnia - Nasdaq
Harmony Biosciences stock tumbles after FDA setback By Investing.com - Investing.com Australia
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia - Business Wire
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Down 31.8% in January - MarketBeat
VCYT: 3 Emerging Biotech Firms Pioneering Next-Gen Therapies - StockNews.com
Earnings Alert: Harmony Biosciences Sets Date for Critical Q4 & FY2024 Financial Report - StockTitan
HRMY or ONC: Which Is the Better Value Stock Right Now? - MSN
Long Term Trading Analysis for (HRMY) - Stock Traders Daily
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $55.00 Average Target Price from Brokerages - MarketBeat
HRMY FY2024 EPS Estimate Raised by Cantor Fitzgerald - MarketBeat
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Shares Not Telling The Full Story - Simply Wall St
Deutsche Bank Aktiengesellschaft Begins Coverage on Harmony Biosciences (NASDAQ:HRMY) - MarketBeat
Deutsche Bank sets Harmony Biosciences stock Buy rating, $55 target - MSN
Polaris Capital Management LLC Acquires 13,300 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now - MSN
Plymouth Meeting’s Harmony Biosciences Eyes $3B in Sales with New Treatments on the Way - MSN
Harmony Biosciences Holdings, Inc (HRMY): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Deutsche Bank Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation - MSN
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews - Benzinga
Deutsche Bank sets Harmony Biosciences stock Buy rating, $55 target By Investing.com - Investing.com Nigeria
Deutsche Bank Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy - StreetInsider.com
(HRMY) Proactive Strategies - Stock Traders Daily
Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider? - Inkl
BlackRock, Inc.'s Strategic Acquisition in Harmony Biosciences H - GuruFocus.com
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? - Yahoo Finance
Top 5 US Stocks To Buy In February 2025 - Investing.com
SG Americas Securities LLC Grows Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
HRMY vs. RGEN: Which Stock Is the Better Value Option? - MSN
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia Sells 1,775 Shares - MarketBeat
Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells 1,629 Shares of Stock - MarketBeat
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):